DDrare: Database of Drug Development for Rare Diseases

45. 好酸球性多発血管炎性肉芽腫症
［臨床試験数：27，薬物数：41（DrugBank：18），標的遺伝子数：18，標的パスウェイ数：98］

Searched query = "Eosinophilic granulomatosis with Polyangiitis", "EGPA", "Eosinophilic multiple vasculitis granulomatous disease", "Allergic granulomatous angiitis", "Churg-Strauss syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Anti-thymocyte globulin; Azathioprine; Benralizumab; CYCLOPHOSPHAMIDE; Corticosteroid; Corticosteroid and azathioprine; Cyclophosphamide; Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; Cyclosporine; Filgrastim; Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS); HPC cell infusion; Human normal immunoglobulin; Hydroxychloroquine; Infliximab; L04AC06; MEDI-563; MEPOLIZUMAB; MESNA; Mepolizumab; Mesna; Methotrexate; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Mycophenolate mofetil,methotrexate; NUCALA; Naltrexone; Naltrexone Hydrochloride; Nucala; Nucala 100 mg powder for solution for injection; Placebo (physiological saline); Plaquenil - Hydroxychloroquine 200mg Film coated tablets; Prednisolone; Prednisone; Prednisone, methylprednisolone,cyclophosphamides; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; RITUXIMAB; Rituximab; SB-240563; SB-240563 (mepolizumab)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00307593 (ClinicalTrials.gov)	May 2004	24/3/2006	RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides	Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies	Wegener's Granulomatosis;Churg-Strauss Syndrome;Microscopic Polyangiitis	Drug: Infliximab;Drug: Rituximab	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	Both	20	N/A	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00307593
(ClinicalTrials.gov)

May 2004

24/3/2006

RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies

Wegener's Granulomatosis;Churg-Strauss Syndrome;Microscopic Polyangiitis

Drug: Infliximab;Drug: Rituximab

Assistance Publique - Hôpitaux de Paris

NULL

Completed

18 Years

N/A

Both

N/A

France